Amgen Highlights Long-Term Aimovig Data for Episodic Migraine

It has been two years since Amgen and Novartis won regulatory approval for Aimovig as the first anti-CGRP migraine treatment. New long-term safety and efficacy data highlights the medication's capabilities in allowing patients to maintain fewer migraine days over a period of five years.